Table of Contents

company-logo

Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. It develops PV-10, an investigational autolytic cancer immunotherapy for adult solid tumor cancers, such as melanoma and gastrointestinal tumors, including hepatocellular carcinoma; colorectal cancer metastatic to the liver; neuroendocrine tumors metastatic to the liver; uveal melanoma metastatic to the liver; and pediatric solid tumor cancers, such as neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma. The company is also developing oral formulations of current good manufacturing practice rose bengal sodium (cGMP RBS) for the treatment of adult solid tumor cancers, such as head and neck, breast, testicular, and colorectal cancers; pediatric blood cancers, including leukemia; coronavirus, an acute respiratory syndrome; multi-drug resistant bacteria, such as gram-negative bacteria; and for eye diseases, including infectious keratitis. In addition, it develops PH-10, an investigational immuno-dermatology agent for the treatment of inflammatory dermatoses, such as psoriasis and atopic dermatitis. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was incorporated in 2002 and is based in Knoxville, Tennessee.

Provectus Biopharmaceuticals Dividend Announcement

• Provectus Biopharmaceuticals does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Provectus Biopharmaceuticals dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Provectus Biopharmaceuticals Dividend History

Provectus Biopharmaceuticals Dividend Yield

Provectus Biopharmaceuticals current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Provectus Biopharmaceuticals stock? Use our calculator to estimate your expected dividend yield:

Provectus Biopharmaceuticals Financial Ratios

P/E ratio-16.39
PEG ratio-0.71
P/B ratio-9.15
ROE43.30%
Payout ratio0.00%
Current ratio0.12
Quick ratio0.12
Cash Ratio0.03

Provectus Biopharmaceuticals Dividend FAQ

Does Provectus Biopharmaceuticals stock pay dividends?
Provectus Biopharmaceuticals does not currently pay dividends to its shareholders.
Has Provectus Biopharmaceuticals ever paid a dividend?
No, Provectus Biopharmaceuticals has no a history of paying dividends to its shareholders. Provectus Biopharmaceuticals is not known for its dividend payments.
Why doesn't Provectus Biopharmaceuticals pay dividends?
There are several potential reasons why Provectus Biopharmaceuticals would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Provectus Biopharmaceuticals ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Provectus Biopharmaceuticals has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Provectus Biopharmaceuticals a dividend aristocrat?
Provectus Biopharmaceuticals is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Provectus Biopharmaceuticals a dividend king?
Provectus Biopharmaceuticals is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Provectus Biopharmaceuticals a dividend stock?
No, Provectus Biopharmaceuticals is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Provectus Biopharmaceuticals stocks?
To buy Provectus Biopharmaceuticals you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Provectus Biopharmaceuticals stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.